103 related articles for article (PubMed ID: 4004281)
41. Immunobiology of primary intracranial tumors: IX. Phase I study of human lymphoblastoid interferon.
Mahaley MS; Urso MB; Whaley RA; Staab EV; Williams TE; Guaspari A
J Biol Response Mod; 1984; 3(1):19-25. PubMed ID: 6707697
[TBL] [Abstract][Full Text] [Related]
42. [Clinical tolerance test of recombinant human thrombopoietin].
Zhao Y; Jiang J; Jiao L
Zhonghua Yi Xue Za Zhi; 2001 Dec; 81(24):1508-11. PubMed ID: 16200777
[TBL] [Abstract][Full Text] [Related]
43. The effect of interferon-alpha A on two cases of Japanese encephalitis in Thailand.
Harinasuta C; Nimmanitya S; Titsyakorn U
Southeast Asian J Trop Med Public Health; 1985 Jun; 16(2):332-6. PubMed ID: 2999996
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of pharmacological and immunological effects of human lymphoblastoid interferon given to patients with cancer.
Laszlo J; Huang AT; Brenckman WD; Jeffs C; Koren H; Cianciolo G; Metzgar R; Cashdollar W; Cox E; Buckley CE; Tso CY; Lucas VS
Cancer Res; 1983 Sep; 43(9):4458-66. PubMed ID: 6603265
[TBL] [Abstract][Full Text] [Related]
45. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
46. [Bropirimine (U-54461S) phase I clinical studies].
Furue H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1941-9. PubMed ID: 8978802
[TBL] [Abstract][Full Text] [Related]
47. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
48. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
49. Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial.
Lenk H; Tanneberger S; Müller U; Shiga T
Arch Geschwulstforsch; 1988; 58(2):89-97. PubMed ID: 3377652
[TBL] [Abstract][Full Text] [Related]
50. [Effect of human fibroblast interferon on malignant brain tumors].
Nakamura O; Teramoto A; Yamamoto H; Ochiai C; Takakura K; Maruo K; Ueyama Y; Shimamura K
No To Shinkei; 1983 Sep; 35(9):905-11. PubMed ID: 6651989
[TBL] [Abstract][Full Text] [Related]
51. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
52. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
[TBL] [Abstract][Full Text] [Related]
53. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
Furue H
Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
[TBL] [Abstract][Full Text] [Related]
54. [Clinical effects of human fibroblast interferon on malignant tumors].
Ezaki K; Okabe K; Inagaki J; Horikoshi N; Inoue K; Aiba K; Domyo M; Nagata T; Ogawa M
Gan To Kagaku Ryoho; 1982 Jan; 9(1):31-7. PubMed ID: 7184362
[TBL] [Abstract][Full Text] [Related]
55. Leukocyte interferon (IFN alpha) in patients with epithelial ovarian carcinoma.
Freedman RS; Gutterman JU; Wharton JT; Rutledge FN
J Biol Response Mod; 1983; 2(2):133-8. PubMed ID: 6644331
[TBL] [Abstract][Full Text] [Related]
56. [Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)].
Ohno R; Kodera Y; Ogura M; Murase T; Emi N; Okumura M; Morishita Y; Nagura E; Minami S; Morishima Y
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2531-6. PubMed ID: 6594973
[TBL] [Abstract][Full Text] [Related]
57. Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.
Weiner LM; Li W; Holmes M; Catalano RB; Dovnarsky M; Padavic K; Alpaugh RK
Cancer Res; 1994 Aug; 54(15):4084-90. PubMed ID: 8033141
[TBL] [Abstract][Full Text] [Related]
58. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
59. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Berek JS; Hacker NF; Lichtenstein A; Jung T; Spina C; Knox RM; Brady J; Greene T; Ettinger LM; Lagasse LD
Cancer Res; 1985 Sep; 45(9):4447-53. PubMed ID: 4028027
[TBL] [Abstract][Full Text] [Related]
60. Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma.
Chaplinski T; Laszlo J; Moore J; Silverman P
Cancer Treat Rep; 1983 Nov; 67(11):1009-12. PubMed ID: 6640552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
